1-苯基-4-甲基吡唑 | 14766-43-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-苯基-4-甲基吡唑
• 中文别名: 4-甲基-1-苯基-1H-吡唑
• 英文名称: 4-methyl-1-phenyl-1H-pyrazole
• 英文别名: 4-methyl-1-phenylpyrazole；4-methyl-1-phenyl-1H-pyrazole；4-Methyl-1-phenyl-1H-pyrazol；1-Phenyl-4-methyl-pyrazol；4-Methyl-1-phenyl-pyrazol；1-Phenyl-4-methylpyrazole
• CAS: 14766-43-9
• 化学式: C₁₀H₁₀N₂
• 分子量: 158.203
• InChiKey: ADHPAHRITFHGGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  1-苯基-4-甲基吡唑 在 alkaline permanganate 作用下， 生成 1-苯基-1H-吡唑-4-甲酸
  参考文献：
  名称：

  Balbiano; Marchetti, Atti della Accademia Nazionale dei Lincei, Classe di Scienze Fisiche, Matematiche e Naturali, Rendiconti, 1893, vol. <5> 2 I, p. 115

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(4-甲基-1-苯基-1H-吡唑-3-基)-乙酮 在 甲醇 、 sodium hypoiodite 作用下， 生成 1-苯基-4-甲基吡唑
  参考文献：
  名称：

  Birkinshaw; Oxford; Raistrick, Biochemical Journal, 1936, vol. 30, p. 407

  摘要：

  DOI：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• Copper-Catalyzed Arylation of Nitrogen Heterocycles from Anilines under Ligand-Free Conditions
  作者：Dounia Toummini、Anis Tlili、Julien Bergès、Fouad Ouazzani、Marc Taillefer

  DOI：10.1002/chem.201404982

  日期：2014.11.3

  The arylation of pyrazole and derivatives can be achieved by coupling arenediazonium species (formed in situ from anilines) by using a catalytic system that employs low‐toxicity and inexpensive copper metal under very mild and ligand‐free conditions (T=20 °C). From other nitrogen heterocycles, the presence of an additive (NBu4I) significantly improves the efficiency of the catalytic system. These results

  吡唑和衍生物的芳基化反应可以通过使用催化系统偶联槟榔重氮物种（由苯胺原位形成）来实现，该催化系统在非常温和且无配体的条件下（T = 20°C）使用低毒性和廉价的铜金属。与其他氮杂环相比，添加剂（NBu 4 I）的存在可显着提高催化体系的效率。这些结果代表C的第一实施例从芳基重氮物种N键的形成。
• Mild Conditions for Copper-CatalysedN-Arylation of Pyrazoles
  作者：Henri-Jean Cristau、Pascal P. Cellier、Jean-Francis Spindler、Marc Taillefer

  DOI：10.1002/ejoc.200300709

  日期：2004.2

  Copper-catalysed N-arylation of pyrazoles with aryl or heteroaryl bromides or iodides, which can include functional substituents, was performed under the mildest conditions yet described, with excellent yields and selectivity, by the use as catalyst of a combination of cuprous oxide with a set of inexpensive, chelating oxime-type ligands not previously known to promote such reactions. Other original

  铜催化吡唑与芳基或杂芳基溴化物或碘化物（可包括功能性取代基）的 N-芳基化反应是在迄今描述的最温和条件下进行的，通过将氧化亚铜与一套廉价的螯合肟型配体，此前未知可促进此类反应。提供氮和/或氧作为螯合原子的其他原始双齿、三齿或四齿配体也在此类芳基化中成功测试。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004)
• 6-0-carbamoyl ketolide antibacterials
  申请人：——

  公开号：US20020115620A1

  公开（公告）日：2002-08-22

  6-O-Carbamoyl ketolide antibacterials of the formula: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, X′, Y, and Y′ are as described herein and in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.

  其中R1、R2、R3、R4、R5、R6、X、X'、Y和Y'如本文所述，并且其中取代基具有描述中指示的含义。这些化合物可用作抗菌剂。
• [EN] DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS<br/>[FR] INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE 2
  申请人：PFIZER

  公开号：WO2013150416A1

  公开（公告）日：2013-10-10

  Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H- imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

  这里描述了抑制二酰基甘油酰基转移酶2（DGAT2）活性的嘌呤衍生物，即式I的3H-咪唑并[4,5-b]嘧啶和1H-咪唑并[4,5-d]吡嗪，以及它们在治疗相关动物疾病中的用途。